Metrics to compare | DIABIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDIABIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −4.1x | −0.4x | |
PEG Ratio | 0.00 | −0.07 | 0.00 | |
Price/Book | 0.0x | 2.3x | 2.6x | |
Price / LTM Sales | 0.0x | 17.0x | 3.0x | |
Upside (Analyst Target) | 0.0% | 260.6% | 57.3% | |
Fair Value Upside | Unlock | −19.7% | 8.9% | Unlock |
Diagonal Bio AB (publ) provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. The company offers LAMPlify, a system used to identify the presence of specific genetic markers, such as fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airports. The company was incorporated in 2020 and is based in Lund, Sweden.